Oligometastatic disease in esophagogastric cancer: an update of recommendations on definition, diagnosis, and treatment

T E Kroese; S F C Bronzwaer; R van Hillegersberg; P S N van Rossum; H W M van Laarhoven

doi:10.1016/j.esmogo.2023.08.008

Oligometastatic disease in esophagogastric cancer: an update of recommendations on definition, diagnosis, and treatment

T E Kroese
, S F C Bronzwaer
, R van Hillegersberg
, P S N van Rossum
, H W M van Laarhoven^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

1 Downloads (Pure)

Abstract

Oligometastatic cancer is characterized by the presence of a restricted number of metastatic lesions extending beyond the primary tumor. Until recently, there was a significant lack of agreement concerning the precise definition and optimal treatment strategies for oligometastatic cancer in the context of esophageal or gastric malignancies. Here we provide an overview of the OligoMetastatic Esophagogastric Cancer (OMEC) project which was initiated to develop a multidisciplinary European consensus statement for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer. Additionally, we provide an updated systematic review of published and ongoing clinical studies on local metastasis-directed treatment of oligometastatic esophagogastric cancer.

Original language	English
Article number	100009
Journal	ESMO Gastrointestinal Oncology
Volume	2
DOIs	https://doi.org/10.1016/j.esmogo.2023.08.008
Publication status	Published - Dec 2023

Access to Document

10.1016/j.esmogo.2023.08.008Licence: CC BY

Oligometastatic disease in esophagogastric cancer: an update of recommendations on definition, diagnosis, and treatmentFinal published version, 741 KBLicence: CC BY

1 Comment/Letter to the editor

Corrigendum to ‘Oligometastatic disease in esophagogastric cancer: an update of recommendations on definition, diagnosis, and treatment’: [Volume 2 - Issue C – 2023 2949-8198] (ESMO Gastrointestinal Oncology (2023) 2, (S2949819823000092), (10.1016/j.esmogo.2023.08.008))
Kroese, T. E., van Hillegersberg, R., van Rossum, P. S. N. & van Laarhoven, H. W. M., Mar 2026, In: ESMO Gastrointestinal Oncology. 11, 100236.
Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Open Access
File
3 Downloads (Pure)

Cite this

@article{08c8038365394d94a75e32a9e849f18c,

title = "Oligometastatic disease in esophagogastric cancer: an update of recommendations on definition, diagnosis, and treatment",

abstract = "Oligometastatic cancer is characterized by the presence of a restricted number of metastatic lesions extending beyond the primary tumor. Until recently, there was a significant lack of agreement concerning the precise definition and optimal treatment strategies for oligometastatic cancer in the context of esophageal or gastric malignancies. Here we provide an overview of the OligoMetastatic Esophagogastric Cancer (OMEC) project which was initiated to develop a multidisciplinary European consensus statement for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer. Additionally, we provide an updated systematic review of published and ongoing clinical studies on local metastasis-directed treatment of oligometastatic esophagogastric cancer.",

author = "Kroese, \{T E\} and Bronzwaer, \{S F C\} and \{van Hillegersberg\}, R and \{van Rossum\}, \{P S N\} and \{van Laarhoven\}, \{H W M\}",

note = "{\textcopyright} 2023 The Author(s).",

year = "2023",

month = dec,

doi = "10.1016/j.esmogo.2023.08.008",

language = "English",

volume = "2",

journal = "ESMO Gastrointestinal Oncology",

issn = "2949-8198",

publisher = "Elsevier",

}

TY - JOUR

T1 - Oligometastatic disease in esophagogastric cancer

T2 - an update of recommendations on definition, diagnosis, and treatment

AU - Kroese, T E

AU - Bronzwaer, S F C

AU - van Hillegersberg, R

AU - van Rossum, P S N

AU - van Laarhoven, H W M

PY - 2023/12

Y1 - 2023/12

N2 - Oligometastatic cancer is characterized by the presence of a restricted number of metastatic lesions extending beyond the primary tumor. Until recently, there was a significant lack of agreement concerning the precise definition and optimal treatment strategies for oligometastatic cancer in the context of esophageal or gastric malignancies. Here we provide an overview of the OligoMetastatic Esophagogastric Cancer (OMEC) project which was initiated to develop a multidisciplinary European consensus statement for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer. Additionally, we provide an updated systematic review of published and ongoing clinical studies on local metastasis-directed treatment of oligometastatic esophagogastric cancer.

AB - Oligometastatic cancer is characterized by the presence of a restricted number of metastatic lesions extending beyond the primary tumor. Until recently, there was a significant lack of agreement concerning the precise definition and optimal treatment strategies for oligometastatic cancer in the context of esophageal or gastric malignancies. Here we provide an overview of the OligoMetastatic Esophagogastric Cancer (OMEC) project which was initiated to develop a multidisciplinary European consensus statement for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer. Additionally, we provide an updated systematic review of published and ongoing clinical studies on local metastasis-directed treatment of oligometastatic esophagogastric cancer.

U2 - 10.1016/j.esmogo.2023.08.008

DO - 10.1016/j.esmogo.2023.08.008

M3 - Review article

C2 - 41647727

SN - 2949-8198

VL - 2

JO - ESMO Gastrointestinal Oncology

JF - ESMO Gastrointestinal Oncology

M1 - 100009

ER -

Oligometastatic disease in esophagogastric cancer: an update of recommendations on definition, diagnosis, and treatment

Abstract

Access to Document

Fingerprint

Research output

Corrigendum to ‘Oligometastatic disease in esophagogastric cancer: an update of recommendations on definition, diagnosis, and treatment’: [Volume 2 - Issue C – 2023 2949-8198] (ESMO Gastrointestinal Oncology (2023) 2, (S2949819823000092), (10.1016/j.esmogo.2023.08.008))

Cite this